EGLN1 and neoplasm: EGLN1, in particular, has been described as a tumor suppressor in colorectal and pancreatic cancer38,39, as a pro-oncogenic factor in acute myeloid leukemia and in lung and ovarian carcinoma40–42, and as having dual roles depending on the study in breast and hepatocellular carcinomas43–46.